The answer was that it remains to be seen during phase 3
use medical oversight or oral NR/NMN instead A history of cancer, gallbladder disease, or diabetic retinopathy, and concurrent glucose-lowering medications or anticoagulants that may need adjustment, are the profiles that warrant clinical oversight before starting
Endocr Connect 6:R99R120
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
P., Mulligan, K., Schambelan, M., Murphy, E
These peptides transmit "satiety" signals because they promote the termination of the food that is in progress and do not delay the subsequent initiation of the food and affect the food intake if it is released between meals [12]